GlassScriptPhysician profile
Nuzhat A Chalisa
NPI 1184686909
$11,295.06
in general payments reported to CMS, 2019-2025
54 companies · $4,000 in 2025
The $4,000 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,035 · 2020: $678 · 2021: $1,137 · 2022: $1,417 · 2023: $1,310 · 2024: $717 · 2025: $4,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,071 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,523 · Travel and Lodging: $416 · Entertainment: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,071.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,523.00 |
| Travel and Lodging | $416.19 |
| Entertainment | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $4,662.15 | 2019-2025 | |
| Novo Nordisk INC | $1,273.77 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Medtronic, INC. | $610.31 | 2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $585.60 | 2019-2024 | Airsupra |
| Abbott Laboratories | $564.96 | 2020-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Corcept Therapeutics | $424.95 | 2019-2024 | Korlym |
| Insulet Corporation | $322.08 | 2020-2025 | Omnipod |
| Dexcom, INC. | $232.65 | 2022-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Lilly USA, LLC | $225.48 | 2019-2024 | Zepbound, Reyvow, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.21 | 2020-2023 | Jardiance, Synjardy, Tradjenta |
| Emd Serono, INC. | $150.30 | 2019-2025 | |
| Becton, Dickinson and Company | $145.19 | 2019 | |
| Abbvie INC. | $143.93 | 2019-2023 | Linzess, Viberzi |
| Bayer Healthcare Pharmaceuticals INC. | $137.42 | 2022-2023 | |
| Intuity Medical INC | $123.92 | 2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nuzhat Chalisa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.